Vizarsin is the Upcoming Viagra Competitor

The famous Slovenian drug maker, Krka is set to launch a new major rival to Pfizer’s Viagra called “Vizarsin”.

Vizarsin is a generic form of Viagra that contains the same active ingredient, namely sildenafil citrate, and has the same effective results in treating erectile dysfunction.

This new generic Viagra will be available in three doses: 25mg, 50mg and 100mg. The pills will be white rather than blue (Viagra’s original color). And most importantly, this generic equivalent will be about 30% cheaper than the brand name Viagra.

The European Medicines Agency (EMEA) has approved and recommended this new medication.

Krka is now selling Vizarsin in Slovenia, but as soon as Pfizer’s patents on Viagra expire (mostly in 2012), Krka shall be granted authorization to start marketing Vizarsin in the European Union and other parts of the world.

There have been many attempts by numerous competitors to make and market generic versions of Viagra (sildenafil citrate) since the drug’s approval in 1998, but none of them succeeded as Pfizer always had the power of law (patent protection) to shut them down. The only FDA approved and real rivals of Viagra so far are: Cialis (tadalafil) and Levitra (vardenafil).